DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Catapres (Clonidine Hydrochloride) - Indications and Dosage



Catapres® (clonidine hydrochloride USP) is indicated in the treatment of hypertension. Catapres may be employed alone or concomitantly with other antihypertensive agents.



The dose of Catapres® (clonidine hydrochloride USP) must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration.

Initial Dose

0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.

Maintenance Dose

Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses. Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed.

Renal Impairment

Dosage must be adjusted according to the degree of impairment, and patients should be carefully monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine following dialysis.


Catapres® (clonidine hydrochloride USP) is supplied in scored oval tablets containing 0.1 mg, 0.2 mg or 0.3 mg of clonidine hydrochloride.

ColorMarkingBottle of 100Bottle of 1000Unit Dose of 100
0.1TanBI 6NDC0597-0006-01NDC0597-0006-10NDC0597-0006-61
0.2OrangeBI 7NDC0597-0007-01NDC0597-0007-10NDC0597-0007-61
0.3PeachBI 11NDC0597-0011-01

Store at 25°C (77°F).
Excursions permitted to 15-30°C (59-86°F).
(See USP controlled room temperature).
Dispense in tight, light-resistant container.

Distributed by
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877

Manufactured by
Promeco S.A. de C.V./(Boehringer Ingelheim-México)
México City, D.F.

Licensed from
Boehringer Ingelheim
International GmbH
Printed in U.S.A. 4/98

340066/ US/ 2

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015